SCHEDULE 13G/A: Point72 Entities and Steven A. Cohen Disclose 7.0% Stake in Alto Neuroscience

Point72 Asset Management, its affiliates, and founder Steven A. Cohen have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 7.0% in Alto Neuroscience, Inc.'s common stock as of March 31, 2025.

Summary

• Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., Point72 Biotech Private Investments, LLC, Differentiated Ventures Investments, LLC, 72 Investment Holdings, LLC, and Steven A. Cohen have filed an Amendment No. 2 to Schedule 13G.
• The filing reports beneficial ownership of common stock in Alto Neuroscience, Inc. (CUSIP: 02157Q109).
• As of March 31, 2025, Steven A. Cohen, through his controlled entities, beneficially owns an aggregate of 1,907,831 shares, representing 7.0% of Alto Neuroscience, Inc.'s common stock.
• Point72 Asset Management, L.P. and Point72 Capital Advisors, Inc. each report shared voting and dispositive power over 1,240,053 shares, representing 4.6% of the class.
• Point72 Biotech Private Investments, LLC, Differentiated Ventures Investments, LLC, and 72 Investment Holdings, LLC each report shared voting and dispositive power over 667,778 shares, representing 2.5% of the class.
• The shares are held under shared voting and dispositive power, with no sole voting or dispositive power reported by any of the filing persons.
• The filing states that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the disclosure of a significant stake by a reputable investment firm, which can be interpreted as a positive signal for the company, although the filing itself is purely factual.

Positives

• The disclosure of a significant stake by a prominent investment firm like Point72 and its founder Steven A. Cohen could be viewed as a vote of confidence in Alto Neuroscience, Inc.

Negatives

• This filing is a standard ownership disclosure and does not inherently contain negative financial or operational information about Alto Neuroscience, Inc.

Risks

• NA

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding Alto Neuroscience, Inc.'s future performance or operations.

Industry Context

The filing indicates a significant investment by a major hedge fund in a biotechnology company. Such investments can signal institutional interest in the sector or specific company's pipeline, potentially influencing market perception within the biotech industry.

Related Party Transactions

• The filing details the relationships between the various Point72 entities and Steven A. Cohen, clarifying how beneficial ownership is attributed across the group due to control and management agreements.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially influence stock trading activity.
• Company Management: Awareness of a large, active institutional investor may influence strategic decisions, although the filing states no intent to change or influence control.

Key Dates

Keywords

Alto Neuroscience, Point72 Asset Management, Steven A. Cohen, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Biotech, Investment Holdings